logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Commentary

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S,  et al.
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...
Journal Article
|
Commentary

The STREAM trial: missed opportunities and lessons for future clinical trials

Loveday M, Reuter A, Furin J, Seddon JA, Cox HS
2019-03-22 • Lancet Infectious Diseases
2019-03-22 • Lancet Infectious Diseases
Final results of the STREAM trial were presented at the 2018, 49th Union World Conference on Lung Health, held in The Hague, The Netherlands. STREAM is a randomised controlled trial comp...
Journal Article
|
Case Report/Series

Outcomes of children born to pregnant women with drug-resistant tuberculosis treated with novel drugs in Khayelitsha, South Africa: a report of five patients

Mohr-Holland E, Daniels J, Furin J, Loveday M, Mudaly V,  et al.
2021-05-01 • Pediatric Infectious Disease Journal
2021-05-01 • Pediatric Infectious Disease Journal
This brief report presents a series of 5 pregnant women treated for rifampicin-resistant tuberculosis with the novel drugs bedaquiline, delamanid, and linezolid as part of an optimized b...
Journal Article
|
Research

“This is not my body:” Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis

Loveday M, Hlangu S, Larkan LM, Cox HS, Daniels J,  et al.
2021-10-18 • PLOS One
2021-10-18 • PLOS One
BACKGROUND
There are few data on the on post-treatment experiences of people who have been successfully treated for rifampicin-resistant (RR-)TB.

OBJECTIVE
To describe ...